系统性红斑狼疮、类风湿关节炎和非霍奇金淋巴瘤患者对利妥昔单抗不良反应输注反应发生情况的差异——谜题变体
Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations.
作者信息
Gilaberte Reyzabal Sergio, Isenberg David
机构信息
Internal Medicine Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom.
出版信息
Front Med (Lausanne). 2022 May 16;9:882891. doi: 10.3389/fmed.2022.882891. eCollection 2022.
Abstract
It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies.
摘要
已明确利妥昔单抗治疗对B细胞恶性肿瘤和自身免疫性风湿性疾病均有用。然而，这种治疗与过敏反应风险增加相关。我们回顾了这些反应在不同情况下发生的频率。当利妥昔单抗用于治疗类风湿关节炎和系统性红斑狼疮时，这些反应似乎较少见，这可能是因为这些患者在使用利妥昔单抗时总是同时使用类固醇，而在治疗B细胞恶性肿瘤时不一定如此。
相似文献
1
Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations.系统性红斑狼疮、类风湿关节炎和非霍奇金淋巴瘤患者对利妥昔单抗不良反应输注反应发生情况的差异——谜题变体
Front Med (Lausanne). 2022 May 16;9:882891. doi: 10.3389/fmed.2022.882891. eCollection 2022.
2
Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review.利妥昔单抗方案治疗后非霍奇金淋巴瘤患者合并肺孢子菌肺炎：2 例报告并文献复习。
J Thorac Dis. 2013 Aug;5(4):E162-6. doi: 10.3978/j.issn.2072-1439.2013.08.35.
3
[Rituximab in systemic lupus erythematosus. Part II: review of clinical experience].[利妥昔单抗治疗系统性红斑狼疮。第二部分：临床经验综述]
Pol Merkur Lekarski. 2010 Aug;29(170):135-40.
4
[Rituximab in systemic lupus erythematosus. Part I. Theoretical basis].[利妥昔单抗治疗系统性红斑狼疮。第一部分。理论基础]
Pol Merkur Lekarski. 2010 Aug;29(170):131-4.
5
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
6
Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.利妥昔单抗治疗非霍奇金淋巴瘤患者时的输注期不良反应。
Arch Med Res. 2013 Oct;44(7):549-54. doi: 10.1016/j.arcmed.2013.09.011. Epub 2013 Oct 8.
7
Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.抗B细胞疗法（利妥昔单抗）在自身免疫性疾病治疗中的应用。
Lupus. 2005;14(3):210-4. doi: 10.1191/0961203305lu2138oa.
8
Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.类风湿关节炎患者接受利妥昔单抗治疗后诱发银屑病：病例报告及文献复习。
Rheumatol Int. 2013 Nov;33(11):2927-30. doi: 10.1007/s00296-012-2581-3. Epub 2012 Nov 8.
9
B cell depletion: rituximab in glomerular disease and transplantation.B细胞耗竭：利妥昔单抗在肾小球疾病和移植中的应用
Nephron Extra. 2013 Dec 31;3(1):125-30. doi: 10.1159/000356050. eCollection 2013 Jan.
10
Current perspective on rituximab in rheumatic diseases.利妥昔单抗在风湿性疾病中的当前观点。
Drug Des Devel Ther. 2017 Oct 3;11:2891-2904. doi: 10.2147/DDDT.S139248. eCollection 2017.
引用本文的文献
1
Association of rituximab use with adverse events in adults with lymphoma or autoimmune disease: a single center experience.利妥昔单抗在成人淋巴瘤或自身免疫性疾病患者中的使用与不良事件的关联：单中心经验
Front Med (Lausanne). 2025 Apr 25;12:1567886. doi: 10.3389/fmed.2025.1567886. eCollection 2025.
2
Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome.一名对利妥昔单抗不耐受的难治性特发性肾病综合征儿童成功转换为使用奥妥珠单抗治疗
J Clin Med. 2025 Jan 3;14(1):239. doi: 10.3390/jcm14010239.
3
Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.人工智能时代的生物类似药——国际法规及在肿瘤治疗中的应用
Pharmaceuticals (Basel). 2024 Jul 10;17(7):925. doi: 10.3390/ph17070925.
4
A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma.一种新型的泼尼松预处理方案可显著降低新诊断的弥漫性大B细胞淋巴瘤患者使用利妥昔单抗时的输液相关反应。
Oncol Lett. 2023 Apr 28;25(6):258. doi: 10.3892/ol.2023.13844. eCollection 2023 Jun.
本文引用的文献
1
Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis.利妥昔单抗治疗系统性红斑狼疮的不良输注反应：一项回顾性分析。
BMC Rheumatol. 2019 Aug 29;3:32. doi: 10.1186/s41927-019-0082-7. eCollection 2019.
2
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus.抗利妥昔单抗抗体的存在可预测系统性红斑狼疮患者的输液相关反应。
Ann Rheum Dis. 2019 Aug;78(8):1140-1142. doi: 10.1136/annrheumdis-2019-215200. Epub 2019 Mar 28.
3
Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.静脉注射利妥昔单抗后的药物不良反应在血液系统恶性肿瘤中比在自身免疫性疾病中更常见，并且可以通过少数临床和实验室参数的组合来预测：一项对374例患者的回顾性多中心研究结果。
Leuk Lymphoma. 2017 Nov;58(11):2633-2641. doi: 10.1080/10428194.2017.1306648. Epub 2017 Apr 3.
4
Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.门诊输液中心对利妥昔单抗的反应：一项为期5年的回顾
J Allergy Clin Immunol Pract. 2017 Jan-Feb;5(1):107-113.e1. doi: 10.1016/j.jaip.2016.06.022. Epub 2016 Aug 3.
5
The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.在一家三级医院中，用利妥昔单抗治疗 B 细胞恶性肿瘤时，输注相关反应的发生率和风险因素。
Oncology. 2014;86(3):127-34. doi: 10.1159/000357711. Epub 2014 Jan 29.
6
Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab.对利妥昔单抗过敏患者的药物特异性 Th2 细胞和 IgE 抗体。
Int Arch Allergy Immunol. 2012;159(3):321-6. doi: 10.1159/000336839. Epub 2012 Jun 22.
7
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.利妥昔单抗治疗活动性增殖性狼疮性肾炎患者的疗效和安全性：利妥昔单抗狼疮性肾炎评估研究
Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.
8
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.类风湿关节炎患者应用利妥昔单抗的更新共识声明。
Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6.
9
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.类风湿关节炎临床试验中接受利妥昔单抗治疗的患者的长期安全性。
J Rheumatol. 2010 Mar;37(3):558-67. doi: 10.3899/jrheum.090856. Epub 2010 Jan 28.
10
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.抗英夫利昔单抗 IgE 和非 IgE 抗体与输注相关严重过敏反应的诱导。
Allergy. 2010 May;65(5):657-61. doi: 10.1111/j.1398-9995.2009.02280.x. Epub 2009 Nov 27.
Zotero 插件